Deep learning approaches for <i>de novo</i> drug design: An overview

Mingyang Wang,Zhe Wang,Huiyong Sun,Jike Wang,Chao Shen,Gaoqi Weng,Xin Chai,Honglin Li,Dongsheng Cao,Tingjun Hou
DOI: https://doi.org/10.1016/j.sbi.2021.10.001
IF: 7.786
2022-01-01
Current Opinion in Structural Biology
Abstract:De novo drug design is the process of generating novel lead compounds with desirable pharmacological and physiochemical properties. The application of deep learning (DL) in de novo drug design has become a hot topic, and many DLbased approaches have been developed for molecular generation tasks. Generally, these approaches were developed as per four frameworks: recurrent neural networks; encoderdecoder; reinforcement learning; and generative adversarial networks. In this review, we first introduced the molecular representation and assessment metrics used in DL-based de novo drug design. Then, we summarized the features of each architecture. Finally, the potential challenges and future directions of DL-based molecular generation were prospected.
What problem does this paper attempt to address?